Výsledky vyhledávání - "Hirotaka Watase"

Akademický článek

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials

Autor: Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida, Yoshiya Tanaka

Publikováno v: Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-13 (2023)

Abstract Introduction Ozoralizumab (OZR), a tumor necrosis factor alpha (TNFα) inhibitor, is a NANOBODY® compound that binds to TNFα and human serum albumin. The main objective of this study was to analyze the pharmacokinetics (PK) of the drug and

Externí odkaz: https://doaj.org/article/fbe57d38f1144fd98a623e2911891b98

Zobrazit plný text záznamu

Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents

Autor: Mai Watanabe, Michihiko Iijima, Hirotaka Watase, Toshiyuki Marumo, Carlos A. Zarate, Brian Marcy, Ayano Hiroki, Kohnosuke Kinoshita, Shigeyuki Chaki

Publikováno v: The international journal of neuropsychopharmacology. 25(2)

Background TP0473292 (the active ingredient of TS-161) is a prodrug of a novel metabotropic glutamate (mGlu) 2/3 receptor antagonist being developed for the treatment of patients with depression. This study evaluated the safety, tolerability, and pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24fb1f4c68492759f457edb964a86d5c
https://pubmed.ncbi.nlm.nih.gov/34534292

Zobrazit plný text záznamu

Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers

Autor: Hironori Yamasaki, Hirotaka Watase, Noriko Takayama, Tomohiro Sugimoto, Fumihiko Sato, Aya Shinfuku, Sota Kato, Takumi Numazaki, Toshiharu Shimazaki, Jinsei Maruyama, Masaru Mutoh, Masanori Fujiwara, Yasunori Kawakita

Publikováno v: American journal of nephrology. 48(3)

Background: TP0463518 is a novel hypoxia-inducible factor prolyl hydroxylase inhibitor developed to aid in the treatment of anemia associated with chronic kidney disease (CKD) and is expected to increase erythropoietin (EPO) derived from liver. Two p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13160d21eb0c219172a44e552b18a22
https://pubmed.ncbi.nlm.nih.gov/30176654

Zobrazit plný text záznamu

SP331TP0463518, A NOVEL ORAL INHIBITOR OF HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE (HIF-PH) INDUCES ERYTHROPOIETIN SECRETION DOMINANTLY DERIVED FROM LIVER IN NON-DIALYSIS AND HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE

Autor: Noriko Takayama, Toshiharu Shimazaki, Fumihiko Sato, Hirotaka Watase, Tomohiro Sugimoto, Takumi Numazaki, Aya Shinfuku, Kunika Kikumori, Sota Kato, Shota Tokuyama, Yasunori Kawakita, Jinsei Maruyama, Masanori Fujiwara

Publikováno v: Nephrology Dialysis Transplantation. 33:i456-i456

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5a6d894cd1fd48031f10ea32206a395
https://doi.org/10.1093/ndt/gfy104.sp331

Zobrazit plný text záznamu

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus

Autor: Hirohisa Omiya, Hideaki Jinnouchi, Hirotaka Watase, Yoshishige Samukawa, Soichi Sakai, Kazunari Nozaki

Publikováno v: Advances in Therapy

Introduction We investigated the impact of reduced renal function on 24-h glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM) treated with luseogliflozin. Methods In this double-blind, placebo-controlled, crossover study, 37

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02eedd3bd01db82a5feff76bab5b4d47

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání